Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Dyskinesia Treatment Pipeline Review H2 2016

Monday, October 17, 2016 4:13
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Dyskinesia – Pipeline Review, H2 2016’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685895-dyskinesia-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
- The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyskinesia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @ https://www.wiseguyreports.com/reports/685895-dyskinesia-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia Overview 8
Therapeutics Development 9
Pipeline Products for Dyskinesia – Overview 9
Pipeline Products for Dyskinesia – Comparative Analysis 10
Dyskinesia – Therapeutics under Development by Companies 11
Dyskinesia – Therapeutics under Investigation by Universities/Institutes 14
Dyskinesia – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Dyskinesia – Products under Development by Companies 18
Dyskinesia – Products under Investigation by Universities/Institutes 21
Dyskinesia – Companies Involved in Therapeutics Development 22
Adamas Pharmaceuticals, Inc. 22
Addex Therapeutics Ltd 23
Advicenne 24
Astraea Therapeutics, LLC 25
Bionomics Limited 26
Catalyst Biosciences, Inc. 27
Catalyst Pharmaceuticals, Inc. 28
Clevexel Pharma SAS 29
Contera Pharma ApS 30
EpiVax, Inc. 31
Heptares Therapeutics Limited 32
Hua Medicine (Shanghai) Ltd. 33
Integrative Research Laboratories Sweden AB 34
Ipsen S.A. 35
Merz Pharma GmbH & Co. KgaA 36
MitoDys Therapeutics Limited 37
Neurim Pharmaceuticals Ltd 38
Neurocrine Biosciences, Inc. 39
Neurolixis Inc. 40
Osmotica Pharmaceutical Corp. 41
Otsuka Holdings Co., Ltd. 42
Phenomenome Discoveries, Inc. 43
Revance Therapeutics, Inc. 44
Sage Therapeutics, Inc. 45
SciFluor Life Sciences, LLC 46
SOM Innovation Biotech SL 47
Synchroneuron Inc. 48
Teva Pharmaceutical Industries Ltd. 49
Dyskinesia – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
(dextromethorphan + quinidine sulfate) – Drug Profile 62
A2M-13677 – Drug Profile 67
abobotulinumtoxin A – Drug Profile 68
acamprosate calcium SR – Drug Profile 72
amantadine hydrochloride ER – Drug Profile 74
amantadine hydrochloride ER – Drug Profile 80
AT-127 – Drug Profile 81
AT-326 – Drug Profile 82
AT-403 – Drug Profile 83
befiradol – Drug Profile 84
CPP-115 – Drug Profile 86
CVXL-0107 – Drug Profile 90
deutetrabenazine ER – Drug Profile 91
dipraglurant ER – Drug Profile 95
dipraglurant IR – Drug Profile 96
Drug for Dyskinesia – Drug Profile 100
HTL-14242 – Drug Profile 101
incobotulinumtoxin A – Drug Profile 102
IRL-790 – Drug Profile 105
JM-010 – Drug Profile 106
MLR-1019 – Drug Profile 108
NBI-640756 – Drug Profile 109
Neu-120 – Drug Profile 110
Neu-240 – Drug Profile 111
onabotulinumtoxinA – Drug Profile 112
PEUN-3 – Drug Profile 113
PPI-1011 – Drug Profile 114
remeglurant – Drug Profile 115
RT-002 – Drug Profile 116
SAGE-217 – Drug Profile 118
sepranolone – Drug Profile 120
SK-609 – Drug Profile 127
Small Molecule for Dyskinesia – Drug Profile 128
Small Molecule for Dyskinesia and Hyperkinesia – Drug Profile 129
Small Molecules for Neurodegenerative Disease – Drug Profile 130
Small Molecules for Tardive Dyskinesia – Drug Profile 131
Small Molecules to Antagonize GPCR for Central Nervous System Diseases – Drug Profile 132
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia – Drug Profile 133
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders – Drug Profile 134
Small Molecules to Antagonize mGluR5 for Dyskinesia – Drug Profile 135
Small Molecules to Target Ion Channels for CNS Disorders – Drug Profile 136
SOM-3355 – Drug Profile 137
TC-8831 – Drug Profile 138
tetrabenazine – Drug Profile 139
valbenazine tosylate – Drug Profile 140
Dyskinesia – Dormant Projects 146
Dyskinesia – Discontinued Products 149
Dyskinesia – Product Development Milestones 150
Featured News & Press Releases 150
Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 165
Disclaimer 166

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685895

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.